Previous Study: TRIO036

Studies & Results

TRIO038

A randomized, multicenter, open-label, two-arm, phase II, neoadjuvant study evaluating the efficacy, safety, and pharmacokinetics of GDC-9545 plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with estrogen receptor-positive and HER2-negative untreated early breast cancer

View FDA Study View EU Study

Presentations

SABCS 2020

Hurvitz S, et al.

Phase II neoadjuvant study of GDC-9545 + palbociclib (palbo) vs anastrozole (A) + palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC)

ESMO Congress 2021

Sara Hurvitz

Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase 2 coopERA BC study

ASCO 2022

Fasching PA, et al.

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org